×
0.000515995872032921 0.00584107327141378 0.00670794633642926 0.00619195046439615 -0.0227038183694531 -0.0773993808049536 -0.0712074303405574 -0.0712074303405574
Stockreport

ImmunoMedics Should Be On Your Radar Before Phase 2 Breast Cancer Data Update [Seeking Alpha]

IMMUNOMEDICS (IMMU)  More Company Research Source: Seeking Alpha
Last immunomedics earnings: 2/8 04:15 pm Check Earnings Report
PDF ImmunoMedics Should Be On Your Radar Before Phase 2 Breast Cancer Data UpdateSummaryUpdated phase 2 Metastatic Triple-Negative Breast cancer data should act as a major catalyst for the stock.ImmunoMedics is nearing the first quarter of 2018 when it will file for its Biologics License Application to the FDA for accelerated approval of IMMU-132.Early phase 2 data in Metastatic Triple-Negative Breast cancer patients already achieved over the threshold set by the FDA for accelerated approval for this patient population.Should ImmunoMedics obtain accelerated approval in 2018, it is likely that it will have to raise more capital to launch IMMU-132 on the market.A late-stage study known as ASCENT has already been initiated, and will act as a post-marketing study for the FDA. The outcome will determine if IMMU-132 can continue to remain on the market. [Read more]

IMPACT SNAPSHOT EVENT TIME: IMMU
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS